Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Zenas BioPharma, Inc.
(ZBIO)
NASDAQ
:ZBIO
ZBIO
Zenas BioPharma, Inc.
Overview
Analyst Forecasts
AI Stock Analysis
Popular
Dividends
Earnings
Ownership
Financials
Statistics
New
Technical Analysis
Historical Prices
New
News & Insights
Chart
More
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
Zenas BioPharma, Inc. (ZBIO) Stock News & Sentiment
Compare
Follow
157
Followers
Premium
Ratings
Promising Developments in Zenas BioPharma’s Orelabrutinib Drive Buy Rating Amidst Competitive Advantage and Expected Share Price Upside
12d ago
ZBIO
Premium
Ratings
Buy Rating Reaffirmed for Zenas BioPharma: Promising Orelabrutinib Developments and Autoimmune Platform Potential
12d ago
ZBIO
Premium
Company Announcements
Zenas BioPharma Approves 2026 Inducement Plan
13d ago
8K
ZBIO
Premium
Company Announcements
Zenas BioPharma Reports Q3 2025 Financial Results
1M ago
ZBIO
Premium
Ratings
Zenas BioPharma’s Promising Autoimmune Platform and Buy Rating Reinforced by Advancements in Obexelimab and Orelabrutinib Trials
2M ago
ZBIO
Premium
Ratings
Zenas BioPharma, Inc.: Promising Outlook with Positive Clinical Results and Strong Financial Position Supporting Buy Rating
2M ago
ZBIO
Premium
Ratings
Optimistic Buy Rating for Zenas BioPharma Driven by Promising Clinical Trials and Strong Financial Position
2M ago
ZBIO
More ZBIO News >
ZBIO News on the Web
All News
Bearish News
Bullish News
2025-12-24
Evercore ISI Sticks to Its Buy Rating for Zenas BioPharma, Inc. (ZBIO)
TipRanks News
Neutral
2025-12-22
Zenas BioPharma Grants 300,000 Stock Options to New Hires at $32.59—What Does This Signal for Investors?
Market Chameleon
Neutral
2025-12-22
Zenas BioPharma Grants 300,000 Stock Options to New Hires at $32.59—What Does This Signal for Investors?
Market Chameleon
Neutral
2025-12-22
Citi adds 'upside 90-day catalyst watch' on Zenas into data
The Fly
Neutral
2025-12-22
Why Zenas BioPharma, Inc.’s (ZBIO) Stock Is Up 6.04%
AAII
Neutral
2025-12-19
Why Zenas BioPharma, Inc.’s (ZBIO) Stock Is Up 5.90%
AAII
Neutral
2025-12-16
Why Zenas BioPharma, Inc.’s (ZBIO) Stock Is Up 5.25%
AAII
Neutral
2025-12-15
Zenas BioPharma Approves 2026 Inducement Plan
TipRanks News
Neutral
78
Results | Showing
1
out of
10
News Score - Last 7 Days
Neutral
ZBIO
Sector Average
Media Buzz
This Week
4 articles
Weekly Average
2.5 articles
News Sentiment
This Week
59%
Sector Average
58%
See how Bullish or Bearish a stock is based on its recent media coverage.
This score is generated using a formula that combines
Media Buzz
and
News Sentiment
.
Media Coverage Analysis
The historical news coverage of this asset in the last three months.
FAQ
What is ZBIO’s Media Buzz Sentiment?
4 articles about ZBIO were published this week. In an average week, 2.5 articles are published.
What is ZBIO’s weekly average amount of articles?
In an average week, 2.5 articles about ZBIO are published.
What is ZBIO’s News Sentiment?
59% of articles about ZBIO were positive this week, compared to its sector average of 58%.
Healthcare Stocks that are Trending in the News
DVAX
Dynavax
AGIO
Agios Pharma
ADUS
Addus Homecare
ENSG
The Ensign Group
NVO
Novo Nordisk
Showing the stocks with the most bullish news sentiment over the past week
See the stocks with the most bullish news sentiment in the sector
Upgrade Now
You need to enable JavaScript to run this app.